{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T09:31:09Z","timestamp":1791192669706,"version":"4.1.0"},"reference-count":28,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2014,11,28]],"date-time":"2014-11-28T00:00:00Z","timestamp":1417132800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Hematol"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1007\/s12185-014-1705-9","type":"journal-article","created":{"date-parts":[[2014,12,2]],"date-time":"2014-12-02T14:47:51Z","timestamp":1417531671000},"page":"133-139","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Combined use of bortezomib, cyclophosphamide, and dexamethasone induces favorable hematological and organ responses in Japanese patients with amyloid light-chain amyloidosis: a single-institution retrospective study"],"prefix":"10.1007","volume":"101","author":[{"given":"Yoshitaka","family":"Kikukawa","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromichi","family":"Yuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sinya","family":"Hirata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhiko","family":"Ide","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotomo","family":"Nakata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshikazu","family":"Miyakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naofumi","family":"Matsuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kisato","family":"Nosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Yonemura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tatsuya","family":"Kawaguchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroyuki","family":"Hata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mitsuya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaka","family":"Okuno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2014,11,28]]},"reference":[{"key":"1705_CR1","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1182\/blood.V79.7.1817.1817","volume":"79","author":"R Kyle","year":"1992","unstructured":"Kyle R, Linos A, Beard C, Linke R, Gertz M, O\u2019Fallon W, et al. Incidence and natural history of primary systemic amyloidosis in Olmsted County, Minnesota, 1950 through 1989. Blood. 1992;79:1817\u201322.","journal-title":"Blood"},{"key":"1705_CR2","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1016\/S0140-6736(03)13396-X","volume":"361","author":"A Dispenzieri","year":"2003","unstructured":"Dispenzieri A, Kyle R, Gertz M, Therneau T, Miller W, Chandrasekaran K, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet. 2003;361:1787\u20139.","journal-title":"Lancet"},{"key":"1705_CR3","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.3109\/10428194.2010.524329","volume":"51","author":"MA Gertz","year":"2010","unstructured":"Gertz MA, Lacy MQ, Dispenzieri A, Hayman SR, Kumar SK, Dingli D, et al. Autologous stem cell transplant for immunoglobulin light chain amyloidosis: a status report. Leuk Lymphoma. 2010;51:2181\u20137.","journal-title":"Leuk Lymphoma"},{"key":"1705_CR4","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1182\/blood-2011-07-370031","volume":"119","author":"S Madan","year":"2012","unstructured":"Madan S, Kumar SK, Dispenzieri A, Lacy MQ, Hayman SR, Buadi FK, et al. High-dose melphalan and peripheral blood stem cell transplantation for light-chain amyloidosis with cardiac involvement. Blood. 2012;119:1117\u201322.","journal-title":"Blood"},{"key":"1705_CR5","doi-asserted-by":"crossref","first-page":"3561","DOI":"10.1182\/blood-2007-07-099481","volume":"110","author":"V Sanchorawala","year":"2007","unstructured":"Sanchorawala V, Skinner M, Quillen K, Finn KT, Doros G, Seldin GC, Buadi FK. Long-term outcome of patients with AL amyloidosis treated with high-dose melphalan and stem-cell transplantation. Blood. 2007;110:3561\u20133.","journal-title":"Blood"},{"key":"1705_CR6","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1016\/j.amjmed.2011.04.013","volume":"124","author":"P Kapoor","year":"2011","unstructured":"Kapoor P, Thenappan T, Singh E, Kumar S, Greipp PR. Cardiac amyloidosis: a practical approach to diagnosis and management. Am J Med. 2011;124:1006\u201315.","journal-title":"Am J Med"},{"key":"1705_CR7","doi-asserted-by":"crossref","first-page":"743","DOI":"10.3324\/haematol.2013.095463","volume":"99","author":"G Palladini","year":"2014","unstructured":"Palladini G, Milani P, Foli A, Obici L, Lavatelli F, Nuvolone M, et al. Oral melphalan and dexamethasone grants extended survival with minimal toxicity in AL amyloidosis: long-term results of a risk-adapted approach. Haematologica. 2014;99:743\u201350.","journal-title":"Haematologica"},{"key":"1705_CR8","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1007\/s12185-013-1294-z","volume":"97","author":"R Watanabe","year":"2013","unstructured":"Watanabe R, Tokuhira M, Kizaki M. Current approaches for the treatment of multiple myeloma. Int J Hematol. 2013;97:333\u201344.","journal-title":"Int J Hematol"},{"key":"1705_CR9","doi-asserted-by":"crossref","first-page":"4860","DOI":"10.1182\/blood-2012-01-407791","volume":"119","author":"SK Kumar","year":"2012","unstructured":"Kumar SK, Hayman SR, Buadi FK, Roy V, Lacy MQ, Gertz MA, et al. Lenalidomide, cyclophosphamide, and dexamethasone (CRd) for light-chain amyloidosis: long-term results from a phase 2 trial. Blood. 2012;119:4860\u20137.","journal-title":"Blood"},{"key":"1705_CR10","doi-asserted-by":"crossref","first-page":"4387","DOI":"10.1182\/blood-2011-10-388462","volume":"119","author":"C Venner","year":"2012","unstructured":"Venner C, Lane T, Foard D, Rannigan L, Gibbs S, Pinney J, et al. Cyclophosphamide, bortezomib, and dexamethasone therapy in AL amyloidosis is associated with high clonal response rates and prolonged progression-free survival. Blood. 2012;119:4387\u201390.","journal-title":"Blood"},{"key":"1705_CR11","doi-asserted-by":"crossref","first-page":"5384","DOI":"10.1182\/blood-2011-12-396903","volume":"119","author":"E Kastritis","year":"2012","unstructured":"Kastritis E, Terpos E, Roussou M, Gavriatopoulou M, Pamboukas C, Boletis I, et al. A phase 1\/2 study of lenalidomide with low-dose oral cyclophosphamide and low-dose dexamethasone (RdC) in AL amyloidosis. Blood. 2012;119:5384\u201390.","journal-title":"Blood"},{"key":"1705_CR12","doi-asserted-by":"crossref","first-page":"433","DOI":"10.3324\/haematol.2012.073593","volume":"98","author":"G Palladini","year":"2013","unstructured":"Palladini G, Russo P, Milani P, Foli A, Lavatelli F, Nuvolone M, et al. A phase II trial of cyclophosphamide, lenalidomide and dexamethasone in previously treated patients with AL amyloidosis. Haematologica. 2013;98:433\u20136.","journal-title":"Haematologica"},{"key":"1705_CR13","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1002\/ajh.20381","volume":"79","author":"MA Gertz","year":"2005","unstructured":"Gertz MA, Comenzo R, Falk RH, Fermand JP, Hazenberg BP, Hawkins PN, et al. Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): a consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis, Tours, France, 18\u201322 April 2004. Am J Hematol. 2005;79:319\u201328.","journal-title":"Am J Hematol"},{"key":"1705_CR14","doi-asserted-by":"crossref","first-page":"1787","DOI":"10.1093\/eurheartj\/ehs104","volume":"33","author":"JJ McMurray","year":"2012","unstructured":"McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, et al. ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J. 2012;33:1787\u2013847.","journal-title":"Eur Heart J"},{"key":"1705_CR15","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1373\/clinchem.2005.049742","volume":"51","author":"CP Price","year":"2005","unstructured":"Price CP, Newall RG, Boyd JC. Use of protein:creatinine ratio measurements on random urine samples for prediction of significant proteinuria: a systematic review. Clin Chem. 2005;51:1577\u201386.","journal-title":"Clin Chem"},{"key":"1705_CR16","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1111\/j.1440-1797.2006.00564.x","volume":"11","author":"C Lane","year":"2006","unstructured":"Lane C, Brown M, Dunsmuir W, Kelly J, Mangos G. Can spot urine protein\/creatinine ratio replace 24\u00a0h urine protein in usual clinical nephrology? Nephrology. 2006;11:245\u20139.","journal-title":"Nephrology"},{"key":"1705_CR17","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1038\/sj.leu.2404284","volume":"20","author":"BG Durie","year":"2006","unstructured":"Durie BG, Harousseau JL, Miguel JS, Blade J, Barlogie B, Anderson K, et al. International uniform response criteria for multiple myeloma. Leukemia. 2006;20:1467\u201373.","journal-title":"Leukemia"},{"key":"1705_CR18","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1200\/JCO.2009.23.8220","volume":"28","author":"E Kastritis","year":"2010","unstructured":"Kastritis E, Wechalekar AD, Dimopoulos MA, Merlini G, Hawkins PN, Perfetti V, et al. Bortezomib with or without dexamethasone in primary systemic (light chain) amyloidosis. J Clin Oncol. 2010;28:1031\u20137.","journal-title":"J Clin Oncol"},{"key":"1705_CR19","doi-asserted-by":"crossref","first-page":"4391","DOI":"10.1182\/blood-2011-11-390930","volume":"119","author":"JR Mikhael","year":"2012","unstructured":"Mikhael JR, Schuster SR, Jimenez-Zepeda VH, Bello N, Spong J, Reeder CB, et al. Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood. 2012;119:4391\u20134.","journal-title":"Blood"},{"key":"1705_CR20","doi-asserted-by":"crossref","first-page":"1614","DOI":"10.1016\/j.clinthera.2013.08.015","volume":"35","author":"G Shah","year":"2013","unstructured":"Shah G, Kaul E, Fallo S, Cossor F, Smith H, Sprague K, et al. Bortezomib subcutaneous injection in combination regimens for myeloma or systemic light-chain amyloidosis: a retrospective chart review of response rates and toxicity in newly diagnosed patients. Clin Ther. 2013;35:1614\u201320.","journal-title":"Clin Ther"},{"key":"1705_CR21","doi-asserted-by":"crossref","first-page":"43","DOI":"10.2147\/CE.S13838","volume":"6","author":"S Jain","year":"2011","unstructured":"Jain S, Diefenbach C, Zain J. O\u2019Connor OA Emerging role of carfilzomib in treatment of relapsed and refractory lymphoid neoplasms and multiple myeloma. Core Evid. 2011;6:43\u201357.","journal-title":"Core Evid"},{"key":"1705_CR22","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123:1826\u201332.","journal-title":"Blood"},{"key":"1705_CR23","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","volume":"30","author":"AJ Jakubowiak","year":"2012","unstructured":"Jakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, et al. Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma. J Clin Oncol. 2012;30:1960\u20135.","journal-title":"J Clin Oncol"},{"key":"1705_CR24","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M Weers de","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840\u20138.","journal-title":"J Immunol"},{"key":"1705_CR25","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1007\/s00277-013-1910-2","volume":"93","author":"JR Berenson","year":"2014","unstructured":"Berenson JR, Hilger JD, Yellin O, Boccia RV, Matous J, Dressler K, et al. A phase 1\/2 study of oral panobinostat combined with melphalan for patients with relapsed or refractory multiple myeloma. Ann Hematol. 2014;93:89\u201398.","journal-title":"Ann Hematol"},{"key":"1705_CR26","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1007\/s12185-013-1290-3","volume":"97","author":"T Hideshima","year":"2013","unstructured":"Hideshima T, Anderson KC. Histone deacetylase inhibitors in the treatment for multiple myeloma. Int J Hematol. 2013;97:324\u201332.","journal-title":"Int J Hematol"},{"key":"1705_CR27","first-page":"3613","volume":"117","author":"B Paiva","year":"2011","unstructured":"Paiva B, Vidriales MB, Perez JJ, Lopez-Berges MC, Garcia-Sanz R, Ocio EM, et al. The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis, Blood. 2011;117:3613\u20136.","journal-title":"The clinical utility and prognostic value of multiparameter flow cytometry immunophenotyping in light-chain amyloidosis, Blood."},{"key":"1705_CR28","doi-asserted-by":"crossref","first-page":"4319","DOI":"10.1200\/JCO.2013.50.8499","volume":"31","author":"TV Kourelis","year":"2013","unstructured":"Kourelis TV, Kumar SK, Gertz MA, Lacy MQ, Buadi FK, Hayman SR, et al. Coexistent multiple myeloma or increased bone marrow plasma cells define equally high-risk populations in patients with immunoglobulin light chain amyloidosis. J Clin Oncol. 2013;31:4319\u201324.","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1705-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12185-014-1705-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12185-014-1705-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T12:44:16Z","timestamp":1598532256000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12185-014-1705-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,11,28]]},"references-count":28,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["1705"],"URL":"https:\/\/doi.org\/10.1007\/s12185-014-1705-9","relation":{},"ISSN":["0925-5710","1865-3774"],"issn-type":[{"value":"0925-5710","type":"print"},{"value":"1865-3774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,11,28]]}}}